The Europe Joint Pain Injections Market would witness market growth of 7.2% CAGR during the forecast period (2022-2028).
Hyaluronic acid injections are used to restore the lost lubricant in the event of osteoarthritis, a kind of arthritis in which the hyaluronic acid that serves as natural lubrication in the joint degrades. Joint pain injections are typically administered directly into the joints to ensure optimal effectiveness.
A local anesthetic and medication are administered to the patients during the facet joint injection, a minimally invasive technique, to numb the facet joint and relieve discomfort. The healthcare sector is expected to experience significant growth in the coming years, mostly due to the development of "value-based" care models.
This development foreshadows the market's expansion for joint pain injections, which will double in size over the years. The primary driver of facet joint injections during the projection period is likely to be the rising desire for non-surgical therapies. Also, increasing emphasis on efficient pain management may significantly contribute to the overall development of the joint pain injections Market during the evaluation period. Pain specialists use facet joint injections to treat chronic spinal diseases effectively, and they continue to be one of the market players' primary sources of income.
Falls and fractures were the most prevalent and severe health problems that older individuals in England encountered. The human cost includes misery, agony, damage, loss of autonomy, loss of self-assurance, and even death. As a result, health services are both expensive and abundant. According to the Falls and Fracture Consensus Statement, published by Public Health England and the National Falls Prevention Coordination Group in January 2017, the total cost of fragility fractures in the United Kingdom is estimated to be £4.4 billion, of which £1.1 billion is allocated to social care. Fractures of the hip account for roughly two billion dollars of this total. This increases the incidence of joint pains among fracture sufferers, raising the need for joint pain injections in Europe.
The Germany market dominated the Europe Joint Pain Injections Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $648.5 Million by 2028. The UK market is exhibiting a CAGR of 6.4% during (2022 - 2028). Additionally, The France market would experience a CAGR of 8% during (2022 - 2028).
Based on Injection Type, the market is segmented into Interleukin Inhibitors, Hyaluronic Acid Injections, and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Joint Type Channel, the market is segmented into Knee & Ankle, Shoulder & Elbow, Hip Joint, Facet Joints of the Spine, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Joint Pain Injections Market will Hit $9.9 Billion by 2028, at a CAGR of 7.7%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bioventus Inc., Pacira BioSciences, Inc., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Pfizer, Inc., Anika Therapeutics, Inc., Zimmer Biomet Holdings, Inc., Eli Lilly And Company, Ferring Holdings SA, and Sanofi S.A.
By Injection Type
By Distribution Channel
By Joint Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
